Evidence map›Paper›PMID 29405974›Full record

ReviewAdvances in cancer research2018

Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery.

Narsireddy Amreddy, Anish Babu, Ranganayaki Muralidharan, Janani Panneerselvam, Akhil Srivastava, Rebaz Ahmed, Meghna Mehta, Anupama Munshi, Rajagopal Ramesh

Open access · greenAbstract readReview
In one paragraph

Review in Advances in cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 1 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 1 synthesis or guideline pooled it, 285 citations in OpenAlex.

  1. Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Membrane-Coated Iron Oxide (FeInternational journal of nanomedicine · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  18. Review
  19. Article
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Narsireddy AmreddyThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Anish BabuThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Ranganayaki MuralidharanThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Janani PanneerselvamThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Akhil SrivastavaThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Rebaz AhmedThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Graduate Program in Biomedical Sciences, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Meghna MehtaThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Anupama MunshiThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Rajagopal RameshThe University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Graduate Program in Biomedical Sciences, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: rajagopal-ramesh@ouhsc.edu.
University of Oklahoma Health Sciences Center · US

Funding

TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
HuR Targeted Nanotherapy for Lung CancerR01CA167516 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAMESH, RAJAGOPAL · 2013 to 2017
$1.9M
NCI NIH HHS R01 CA167516NIGMS NIH HHS P20 GM103639
6 · The paper itself

Abstract

Effective and safe delivery of anticancer agents is among the major challenges in cancer therapy. The majority of anticancer agents are toxic to normal cells, have poor bioavailability, and lack in vivo stability. Recent advancements in nanotechnology provide safe and efficient drug delivery systems for successful delivery of anticancer agents via nanoparticles. The physicochemical and functional properties of the nanoparticle vary for each of these anticancer agents, including chemotherapeutics, nucleic acid-based therapeutics, small molecule inhibitors, and photodynamic agents. The characteristics of the anticancer agents influence the design and development of nanoparticle carriers. This review focuses on strategies of nanoparticle-based drug delivery for various anticancer agents. Recent advancements in the field are also highlighted, with suitable examples from our own research efforts and from the literature.

Indexed as

AnimalsAntineoplastic AgentsDrug CarriersDrug Delivery SystemsHumansNanoparticlesNeoplasmsAntineoplastic AgentsDrug CarriersChemotherapeuticsDrug deliveryExosomesGene therapyNanoparticleTumor targeting

Identifiers

PMID29405974
PMCPMC6550462
OpenAlexW2774577787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.